Article Details
Retrieved on: 2022-11-07 18:56:54
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca's (AZ) INSIDE-CKD research has demonstrated that Farxiga could cut 33% of healthcare costs by delaying chronic kidney disease (CKD) ...
Article found on: www.pharmatimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here